Cytokinetics, Incorporated (CYTK) News
Filter CYTK News Items
CYTK News Results
|Loading, please wait...|
CYTK News Highlights
- For CYTK, its 30 day story count is now at 9.
- Over the past 28 days, the trend for CYTK's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CYTK are HCM, AMP and DRUG.
Latest CYTK News From Around the Web
Below are the latest news stories about CYTOKINETICS INC that investors may wish to consider to help them evaluate CYTK as an investment opportunity.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
SOUTH SAN FRANCISCO, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2023 it granted stock options to purchase an aggregate of 76,800 shares of common stock to 7 new employees, whose employment commenced in May 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $37.69 per share, which is equal to the closing price of the Company’s common stock on May 31, 20
Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Jefferies Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Thursday, June 8, 2023 at 9:30 AM Eastern Time at the Marriott Marquis in New York, NY.Goldman
Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
Figure 2 REDWOOD-HCM Cohort 4: Angina Symptoms Figure 1 REDWOOD-HCM Cohort 4: Kansas City Cardiomyopathy Questionnaire (KCCQ) Figure 4 REDWOOD-HCM Cohort 4: Cardiac Biomarkers Figure 3 REDWOOD-HCM Cohort 4: New York Heart Association (NYHA) Functional Class Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster presentations at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023. Late Breaking Clinical Trial Title: REDWOOD-HCM-Cohort 4: Aficamten in Non-Obstructive HCMPresenter: Ahmad Masri, M.D. M.S.,
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
Advancement of Additional Cardiac Myosin Inhibitor Expands Specialty Cardiovascular PortfolioSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4021586 (CK-586). CK-586 is a cardiac myosin inhibitor in development for the potential treatment of patients with h
Cytokinetics to Participate in the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:00 AM Eastern Time at the New York Hilton Midtown in New York, NY. Interested parties may access the live webcast of this fireside chat by visiting the Investors & Media section of the Cytokinetics
Analysts' Revenue Estimates For Cytokinetics, Incorporated (NASDAQ:CYTK) Are Surging Higher
Cytokinetics, Incorporated ( NASDAQ:CYTK ) shareholders will have a reason to smile today, with the analysts making...
Cytokinetics, Incorporated (CYTK) Q1 2023 Earnings Call Transcript
Cytokinetics, Incorporated (CYTK)
Q1 2023 Earnings Conference Call
May 04, 2023 04:30 PM ET
Diane Weiser - Senior Vice President of Corporate Communications & Investor Relations
Robert Blum - President & Chief Executive Officer
Fady Malik - Executive Vice President, Research & Development
Stuart Kupfer - Senior Vice President & Chief Medical Officer
Andrew Callos - Executive Vice President & Chief Commercial Officer
Robert Wong - Vice President & Chief Accounting Officer
Ching Jaw - Senior Vice President & Chief Financial Officer
Conference Call Participants
Srikripa Devarakonda - Truist
Salim Syed - Mizuho
Q1 2023 Cytokinetics Inc Earnings Call
Q1 2023 Cytokinetics Inc Earnings Call
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?